Delving into the Latest Updates on LTT Bio-Pharma Co., Ltd. with Synapse

Overview

Basic Info

Introduction

LTT Bio-Pharma is a company that focuses on researching, developing, and producing new drugs and innovative technologies. They specialize in drug delivery systems that ensure the precise delivery of medication to the intended area of the body at the right time. Additionally, they offer drug discovery services and operate a dispensing pharmacy. The company was established in 1988 by Yutaka Mizushima and is headquartered in Tokyo, Japan.

Tags

Respiratory Diseases

Other Diseases

Eye Diseases

Small molecule drug

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	14
Enzyme	1

Top 5 Target	Count

Autophagy protein	2
SOD1(Superoxide dismutase)	1

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-4002) in Patients with dry eye syndrome - Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-4002) in Patients with dry eye syndrome

Start Date11 Apr 2019

Sponsor / Collaborator

LTT Bio-Pharma Co., Ltd.

JPRN-UMIN000021601 / Completed

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-0303) in Patients with dry eye syndrome - Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-0303) in Patients with dry eye syndrome

Start Date13 Mar 2016

Sponsor / Collaborator

LTT Bio-Pharma Co., Ltd.

JPRN-UMIN000009572 / Completed

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Lecithinized Superoxide Dismutase Nebulizer (PC-SOD NE) in Adult Patients with Moderate Idiopathic Pulmonary Fibrosis - Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Lecithinized Superoxide Dismutase Nebulizer (PC-SOD NE) in Adult Patients with Moderate Idiopathic Pulmonary Fibrosis

Start Date18 Jul 2012

Sponsor / Collaborator

LTT Bio-Pharma Co., Ltd.

100 Clinical Results associated with LTT Bio-Pharma Co., Ltd.

Login to view more data

0 Patents (Medical) associated with LTT Bio-Pharma Co., Ltd.

Login to view more data

20

Literatures (Medical) associated with LTT Bio-Pharma Co., Ltd.

01 Jun 2024·Journal of Clinical Oncology

New drugs to prevent oxaliplatin-induced peripheral neuropathy: A double-blind, randomized study.

Author: Sonoda, Hiromichi ; Matsuda, Akihisa ; Yamaguchi, Kensei ; Yamada, Takeshi ; Hata, Taishi ; Munemoto, Yoshinori ; Mizushima, Tohru ; Ikeda, Masataka ; Hirose, Atsushi ; Ishiguro, Atsushi

3568 Background: Postoperative adjuvant chemotherapy for colorectal cancer reduces postoperative recurrence; however, it often causes undesirable adverse events. Oxaliplatin, the mainstay of postoperative adjuvant chemotherapy is particularly likely to cause chemotherapy-induced peripheral neuropathy (CIPN) and hypersensitivity reactions (HSR) that may make it difficult to continue treatment. Various agents have been tested for prevention or treatment of CIPN caused by oxaliplatin, but none have proven effective. Reactive oxygen species contribute oxaliplatin-induced PN; therefore, super oxide dismutase (SOD) could potentially suppress them, but its very short serum half-life has made clinical application difficult. We developed a lecithinized human copper/zinc SOD (Cu/Zn-SOD) (PC-SOD) in which four phosphatidylcholine derivative molecules are bound covalently to each SOD dimer. Compared with SOD, PC-SOD enhanced stability in plasma and stronger tissue affinity, and exerts therapeutic effects in animal models of several diseases, including CIPN. Methods: This double-blind, randomized study included 90 patients with stage II/III colorectal cancer. All patients were slated to receive 12 cycles of mFOLFOX6. In each cycle, patients received PC-SOD or a placebo immediately before oxaliplatin. The primary endpoint of this study was the number of cycles before NCI-CTCAE Grade 2 (G2) CIPN occurred. One of the secondary endpoints was the number of cycles before DEB-NTC G2 PN occurred. Results: Forty-three patients received PC-SOD. No serious adverse events were observed that could be related to PC-SOD. The incidence of neutropenia, diarrhea, stomatitis, and malaise were lower in the study group, but the differences were not significant. Additionally, 3 patients (7.0%) in the study group and 11 (23.4%) in the placebo group had HSR. Although there was no difference in the number of cycles between the two groups until NCI-CTCAE G2 PN occurred, the study group had a significantly greater number of cycles before DEB-NTC G2 PN compared to the placebo group (P=0.08). The study group had a significantly greater number of cycles before NCI-CTC G1 PN (P=0.01) and HSR (P=0.03) compared to the placebo group. The number of cycles before HSR or NCI-CTCAE G2 PN occurred was greater in the study group , but the difference was not significant. The average total oxaliplatin dose was higher in the study group but the difference was not statistically significant. Conclusions: The primary endpoint did not occur; however, the study group had a significantly greater number of cycles before DEB-NTC G2 PN. Notably, the study group also had a significantly greater number of cycles before HSR. These results show that PC-SOD may suppress HSR as well as PN, both of which limit administration of oxaliplatin. Thus, this drug is expected to improve not only patient quality of life, but also the prognosis of patients. Clinical trial information: 2031210466.

12 Jun 2023·International journal of molecular sciences

Attenuation of LPS-Induced Lung Injury by Benziodarone via Reactive Oxygen Species Reduction.

Article

Author: Mizushima, Tohru ; Tanaka, Ken-Ichiro ; Miura, Keita ; Takafuji, Ayaka ; Ishihara, Tsutomu

As overproduction of reactive oxygen species (ROS) causes various diseases, antioxidants that scavenge ROS, or inhibitors that suppress excessive ROS generation, can be used as therapeutic agents. From a library of approved drugs, we screened compounds that reduced superoxide anions produced by pyocyanin-stimulated leukemia cells and identified benzbromarone. Further investigation of several of its analogues showed that benziodarone possessed the highest activity in reducing superoxide anions without causing cytotoxicity. In contrast, in a cell-free assay, benziodarone induced only a minimal decrease in superoxide anion levels generated by xanthine oxidase. These results suggest that benziodarone is an inhibitor of NADPH oxidases in the plasma membrane but is not a superoxide anion scavenger. We investigated the preventive effect of benziodarone on lipopolysaccharide (LPS)-induced murine lung injury as a model of acute respiratory distress syndrome (ARDS). Intratracheal administration of benziodarone attenuated tissue damage and inflammation via its ROS-reducing activity. These results indicate the potential application of benziodarone as a therapeutic agent against diseases caused by ROS overproduction.

01 Jan 2022·Proceedings for Annual Meeting of The Japanese Pharmacological Society

Influence of fluoro-loxoprofen on gastrointestinal mucosa

Author: Mizushima, Tohru ; Sasaki, Reiichiro ; Jonan, Shizuka ; Masuda, Yuya ; Yamakawa, Naoki ; Amagase, Kikuko

100 Deals associated with LTT Bio-Pharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with LTT Bio-Pharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

Phase 1 Clinical

Phase 2 Clinical

7

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LT-4008 ( Autophagy protein )	Hematologic Neoplasms More	Phase 2
LT-4001	Pulmonary Disease, Chronic Obstructive More	Phase 2
LT-4006	Irritable Bowel Syndrome More	Phase 2
LT-4007 ( Autophagy protein )	Nerve Degeneration More	Phase 2
Lecithin-modified superoxide dismutase ( SOD1 )	Chronic Kidney Diseases More	Phase 2